Wintrust Investments LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

Wintrust Investments LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,431 shares of the company’s stock after selling 2,861 shares during the quarter. Wintrust Investments LLC’s holdings in Johnson & Johnson were worth $5,699,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in JNJ. Beverly Hills Private Wealth LLC increased its holdings in shares of Johnson & Johnson by 64.5% in the 2nd quarter. Beverly Hills Private Wealth LLC now owns 54,362 shares of the company’s stock worth $9,189,000 after purchasing an additional 21,321 shares in the last quarter. AlphaCore Capital LLC increased its holdings in shares of Johnson & Johnson by 15.0% in the 2nd quarter. AlphaCore Capital LLC now owns 12,702 shares of the company’s stock worth $2,102,000 after purchasing an additional 1,658 shares in the last quarter. Summit X LLC increased its holdings in shares of Johnson & Johnson by 2.0% in the 2nd quarter. Summit X LLC now owns 3,776 shares of the company’s stock worth $626,000 after purchasing an additional 75 shares in the last quarter. Humankind Investments LLC increased its holdings in shares of Johnson & Johnson by 13.5% in the 2nd quarter. Humankind Investments LLC now owns 18,023 shares of the company’s stock worth $2,983,000 after purchasing an additional 2,144 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Johnson & Johnson by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock worth $1,463,594,000 after purchasing an additional 430,445 shares in the last quarter. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $149.91 on Tuesday. The stock’s 50-day simple moving average is $154.52 and its 200-day simple moving average is $160.29. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $181.04. The company has a market capitalization of $360.88 billion, a price-to-earnings ratio of 11.13, a PEG ratio of 3.00 and a beta of 0.58. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.14. The company had revenue of $21.35 billion for the quarter, compared to the consensus estimate of $21 billion. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. As a group, analysts expect that Johnson & Johnson will post 10.1 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be given a $1.19 dividend. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Friday. Royal Bank of Canada initiated coverage on Johnson & Johnson in a report on Wednesday, October 4th. They issued an “outperform” rating and a $178.00 price objective for the company. HSBC initiated coverage on Johnson & Johnson in a report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective for the company. Raymond James cut their price target on Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Finally, TheStreet lowered Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday. Eight research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $169.19.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.